These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10070926)

  • 1. Intravenous iron supplementation in end-stage renal disease patients.
    Matzke GR
    Am J Kidney Dis; 1999 Mar; 33(3):595-7. PubMed ID: 10070926
    [No Abstract]   [Full Text] [Related]  

  • 2. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
    Harmankaya O; Eran A
    Ren Fail; 2002 Mar; 24(2):245-7. PubMed ID: 12071600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
    Warady BA; Zobrist RH; Wu J; Finan E;
    Pediatr Nephrol; 2005 Sep; 20(9):1320-7. PubMed ID: 15971073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving target hematocrit in dialysis patients: new concepts in iron management.
    Nissenson AR
    Am J Kidney Dis; 1997 Dec; 30(6):907-11. PubMed ID: 9398140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial.
    Giordano A; Arrigo G; Lavarda F; Colasanti G; Petrini C
    J Nephrol; 2005; 18(2):181-7. PubMed ID: 15931646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing continuous quality improvement strategies for improving iron replacement in hemodialysis patients.
    Trenkle JA
    Nephrol Nurs J; 2001 Oct; 28(5):561-5. PubMed ID: 12143432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Factors influencing responsiveness to treatment in children with renal anemia in end stage renal disease].
    Haliţchi CI; Munteanu M; Brumariu O
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):94-9. PubMed ID: 18677909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Iron supplementation in chronic kidney disease].
    Graczyk M; Dylewska M
    Wiad Lek; 2017; 70(6 pt 2):1215-1218. PubMed ID: 29533917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current recommendations for the treatment of iron deficiency anemia].
    Schaefer RM; Huch R; Krafft A;
    Rev Med Suisse; 2007 Apr; 3(105):874-80. PubMed ID: 17514929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of intravenous iron therapy on novel markers of iron deficiency.
    Chinnappa S; Bhandari S
    Int J Artif Organs; 2010 May; 33(5):297-301. PubMed ID: 20593351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron supplementation in haemodialysis--practical clinical guidelines.
    Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
    Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
    Trivedi HS; Brooks BJ
    Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
    Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
    Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron replacement in rHuEPO-treated dialysis patients: DOQI and beyond.
    Mittman N
    Am J Kidney Dis; 1999 Jul; 34(1):173-6. PubMed ID: 10401035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.